Fig. 2From: Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysisQuality assessment (Cochrane risk of bias tool) for included RCTs. RCT randomized control studyBack to article page